News & Events

Market Analysis Data Streamline the Pharma Brand Planning Process

In the past, many pharma companies followed the same brand planning playbook. These strategies emphasized in-person events and traditional sales strategies, but the pharma market is shifting. In a post–COVID-19 world, live conferences and sales events are out. Healthcare providers (HCPs) are looking for different forms of engagement and leaning toward virtual contacts. More than ever, HCPs want flexible communication that provides valuable information via the channel they prefer.

A fresh, modern approach to brand planning can help maximize your organization’s success. Business intelligence and treatment data will help your company succeed in a competitive marketplace. HCPs can offer valuable insights; they provide a window into the healthcare system and deliver on-the-ground feedback. Read on to learn more about leveraging this information during the brand planning process.

Focus on the essentials
Before you begin a new marketing initiative, ask these 3 vital questions
• Where do we want to be?
• How do we develop a strategy that will take us there?
• How do we apply this strategy in a cost-effective way?

For example, maybe your company has developed a new oncology drug. You want to convince HCPs that your drug is safer than the alternatives. A successful strategy must identify key safety concerns from HCPs and patients. Next, you need materials that address their concerns in a clear, convincing way. Your team also needs to consider potential roadblocks and control costs.

Determine the end-goal of your initiative and break down large goals into small steps. Once you have your goals in mind, zero in on your target audience. A detailed customer profile helps guide your outreach. Your organization can determine what HCPs will play a role in your marketing initiative; you can then refine your marketing strategy on the basis of your target audience.

Considering your target audience and focusing on outreach is a simple step. Unfortunately, some organizations skip this part of the brand planning process. Companies often rush directly into branding and marketing without seeking feedback. These organizations tend to have a laser-focus on their own priorities.

HCPs have their own priorities though, and view treatments from a different perspective. Without targeted research, their concerns may go unnoticed. The resulting gaps in your marketing strategy can be expensive and embarrassing. Robust market analysis data help prevent these roadblocks.

The value of a data-driven initiative
Up-to-date market research is invaluable. Feedback from HCPs also plays a vital role. These twin data streams help your company map the competitive landscape. They also show your organization how to tap into the current pharma market. Data reveal the challenges and pitfalls facing your particular market. They let you address stakeholder concerns and develop a compelling message.

Aptitude Health offers in-depth insight reports and online discussion platforms. These tools help you forge connections with medical experts. HCPs provide the information you need to understand treatment patterns and pain points. Insight reports also reveal trends that may affect your company’s long-term success. Wise companies incorporate market research into every phase of their brand planning. This information lets you target key demographics and avoid costly marketing mistakes.

The rise of digital marketing
There’s no question about it: digital marketing is the new normal. COVID-19 is responsible in part for this shift, but the pandemic has only accelerated trends already underway. For years, HCPs and medical experts have gravitated away from in-person events. Digital channels cut travel time and allow greater flexibility. It’s no surprise that busy HCPs prefer to make virtual connections on their own schedule.

Pharma companies can’t fight the changing tide. To thrive, they need a comprehensive, personalized approach to digital marketing. Companies must identify the right communication channels, then they need to craft integrated messages that can be deployed across multiple platforms.

This can be a daunting task, but companies can tailor their digital approach on the basis of market insights. Insight reports help shift your focus toward patients and subscribers. Market research reveals what appeals to HCPs and patients—and what turns them off. It can also help your company understand which digital channels your audience prefers.

Focus on your audience’s goals
Many pharma companies make the mistake of building their strategy around internal goals. They know what they want from their marketing campaign but forget to consider the needs and preferences of their audience. The result is often an expensive, eye-catching campaign that makes no impact.

The most successful initiatives focus on the audience’s needs and emotions. Twenty-first century audiences are used to content marketing. Each day, they’re exposed to companies that provide sympathetic interest in their concerns. They’re also used to receiving valuable information as part of a marketing initiative. It’s no wonder they expect pharma companies to do the same.

Marketing analysis data can help your company understand what your audience wants, by offering insight into their decision-making process and revealing key concerns.

Don’t forget your stakeholders
Developing a clear, cohesive message not only helps your company communicate with HCPs but also helps strengthen your bond with stakeholders. Market data play a role here, too. With the right data, you can address stakeholder concerns; you can develop a marketing message that speaks both to stakeholders and HCPs. Evidence-based communications can ease their concerns and build confidence. You should maintain a consistent approach with both internal and external contacts. A unified message helps ensure that everyone is striving toward the same goal.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.